 The FDA has lifted the clinical hold on Ocugen Incs NASDAQ: OCGN Phase 23 trial, OCU-002, for Covaxin BBV152, a whole virus inactivated COVID-19 vaccine candidate. In April, the agency paused the trials of the shot, Covaxin, after an inspection of a Bharat Biotech. 